The Cooper Health System
Trial Pipeline
Incentive Spirometry to Improve Outcomes in Lung Cancer Patients Undergoing Concurrent Chemotherapy and Radiation Therapy
NCT06688422
Chronic Subdural Hematoma Treatment With Intra-Arterial Bevacizumab Injection
NCT06510582
The Effect of Bacterial Decolonization Before Skin Cancer Surgery on Infection Rate of Lower Extremity Wounds Left Open to Heal
NCT07142408
Prospective Study to Evaluate High Flow Nasal Cannula With Monitored Anesthesia Care During EBUS Bronchoscopy
NCT05203328
Duration of Immobilization After Reverse Total Arthroplasty for Proximal Humerus Fractures
NCT06133920
Standardized Yoga & Meditation Program for Stress Reduction for Adolescents With Irritable Bowel Syndrome
NCT05719246
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
NCT03906617
Maternal Cancer Diagnosis and Treatment During Pregnancy:a Database for Maternal, Fetal, and Neonatal Outcomes
NCT02749474
Emulated Study of Vitamin D Correction Vs Non-Correction
NCT06366776
Treatment of Neonatal Abstinence Syndrome With Clonidine Versus Morphine as Primary Therapy
NCT03092011
Dendritic Cell Vaccination With Standard Postoperative Chemoradiation for the Treatment of Adult Glioblastoma
NCT04552886
Vitamin D3 Supplementation to Prevent Respiratory Tract Infections
NCT04596657
ACE, Resilience, and Substance Use Disorder: Maternal and Baby Outcomes in the First Year of Life
NCT05731557
Caretaker vs. Routine Blood Pressure Sphygmomanometer
NCT03918486
Intravenous Fluid Therapy for the Treatment of Emergency Department Patients With Migraine Headache
NCT02933060
Reoxygenation After Cardiac Arrest II (REOX II Study)
NCT02698826
Reoxygenation After Cardiac Arrest (REOX Study)
NCT01881243
Use of Dexmedetomidine for Sedation During Flexible Bronchoscopy in Patients With COPD: A Descriptive Study
NCT00401206
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 1 |
| Phase 3 | 29 |
| Phase 4 | 2 |
Therapeutic Areas
What the Pipeline for The Cooper Health System Shows
According to the ClinicalTrials.gov registry, The Cooper Health System is linked to 46 US clinical trials across every stage of research activity. Of those, 36 studies are currently recruiting — about 78% of the sponsor's indexed portfolio — and 8 are already marked complete, representing roughly 17% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for The Cooper Health System reports 31 late-stage studies (Phase 3 and Phase 4 combined) and 4 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for The Cooper Health System is Lung Cancer with 2 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.